Prevention Research
NIAID researchers are actively engaged in the search for an effective vaccine against dengue fever. The vaccine approach that is currently been evaluated at NIAID for efficacy against dengue animal models and human trials is a weakened recombinant version (live- attenuated) of the dengue virus. Other NIAID-funded investigators are working to develop dengue vaccines using different live-attenuated dengue viruses, recombinant proteins, viral vectors, and DNA.
NIAID-supported researchers are also exploring alternate prevention methods, such as targeting dengue virus in the mosquito vector. By preventing dengue viruses from reproducing inside mosquitoes, researchers hope to reduce the transmission of diseases by mosquitoes.
Research Features
New Defense Mechanism against Dengue Identified in Mosquitoes
Modified Mosquitoes Could Save People from Dengue Fever
Infant Immunity May Show Path to Dengue Vaccine
NIAID Scientists Use Reverse Genetics to Develop Potential Dengue Vaccine
Modified Mosquitoes Could Save People from Dengue Fever